Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Musculoskeletal stiffness, Neck pain, Polymyalgia rheumatica
Clinical narrative: 2 days after his 2nd Pfizer COVID vaccine, the patient developed bilateral shoulder, neck bilateral hip pain and prolonged am stiffness that has now been diagnosed as polymyalgia rheumatica.  Symptoms; 2 days after his 2nd Pfizer COVID vaccine, the patient developed bilateral shoulder, neck bilateral hip pain and prolonged am stiffness that has now been diagnosed as polymyalgia rheumatica.  Symptoms; 2 days after his 2nd Pfizer COVID vaccine, the patient developed bilateral shoulder, neck bilateral hip pain and prolonged am stiffness that has now been diagnosed as polymyalgia rheumatica.  Symptoms; 2 days after his 2nd Pfizer COVID vaccine, the patient developed bilateral shoulder, neck bilateral hip pain and prolonged am stiffness that has now been diagnosed as polymyalgia rheumatica.  Symptoms; 2 days after his 2nd Pfizer COVID vaccine, the patient developed bilateral shoulder, neck bilateral hip pain and prolonged am stiffness that has now been diagnosed as polymyalgia rheumatica.  Symptoms; This is a spontaneous report from a contactable consumer. Consumer reported for a 74-year-old male patient. A 74-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: Solution for injection, Batch/Lot number was not reported), dose 2 intramuscularly, administered in arm right on 22Mar2021 13:30 as dose 2, single for COVID-19 immunization, (age at the time of vaccination was 74-year-old). Medical history included, hypertension and nephrolithiasis, from an unknown date and unknown if ongoing. Concomitant medications included aspirin [acetylsalicylic acid] (ASPIRIN [ACETYLSALICYLIC ACID]); cyanocobalamin (B12-VITAMIIN); vitamin d nos (VITAMIN D NOS); lisinopril (LISINOPRIL), (all concomitant medications) taken for an unspecified indication, start and stop date was not reported. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: Solution for injection, Batch/Lot number was not reported), dose 1 intramuscularly, administered in arm right on 26Feb2021 10:00 as dose 1, single for COVID-19 immunization. The patient did not receive any other vaccine prior to COVID-19 Vaccine. The patient did not test COVID-19 positive prior to vaccination. It was unknown if the patient was tested for COVID, post vaccination. It was reported that 2 days after his 2nd Pfizer COVID vaccine, (0n 24Mar2021, 9:00) the patient developed bilateral shoulder, neck bilateral hip pain and prolonged am stiffness that has now been diagnosed as polymyalgia rheumatica. Symptoms continued until current time which was on June 14th. Patient had no symptoms of polymyalgia rheumatica prior to his COVID vaccine. The patient visited the physician office for all the events. Treatment medication included prednisone for all the events. Outcome of all the events was reported as not recovered.   Follow up needed, further information was requested.; Sender's Comments: Based on the information provided in the narrative, the causal association between the suspect drug and the events cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.